Alan Nies Net Worth

The estimated Net Worth of Alan S Nies is at least $154 millier dollars as of 21 May 2023. Alan Nies owns over 9,302 units of Lexicon Pharmaceuticals Inc stock worth over $69,368 and over the last 18 years he sold LXRX stock worth over $0. In addition, he makes $84,552 as Independent Director at Lexicon Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Alan Nies LXRX stock SEC Form 4 insiders trading

Alan has made over 5 trades of the Lexicon Pharmaceuticals Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 9,302 units of LXRX stock worth $15,720 on 21 May 2023.

The largest trade he's ever made was exercising 10,638 units of Lexicon Pharmaceuticals Inc stock on 24 April 2021 worth over $17,978. On average, Alan trades about 1,544 units every 268 days since 2007. As of 21 May 2023 he still owns at least 41,046 units of Lexicon Pharmaceuticals Inc stock.

You can see the complete history of Alan Nies stock trades at the bottom of the page.

Alan Nies biography

Dr. Alan S. Nies M.D. serves as Independent Director of the Company. Dr. Nies has been a director since November 2003. Dr. Nies served in a series of senior management positions during ten years at Merck & Co. Inc. until his retirement in 2002, including senior vice president, clinical sciences. Prior to joining Merck, Dr. Nies spent fifteen years as professor of medicine and pharmacology and head of the Division of Clinical Pharmacology at the University of Colorado Health Sciences Center. Dr. Nies holds a B.S. from Stanford University and an M.D. from Harvard Medical School.

What is the salary of Alan Nies?

As the Independent Director of Lexicon Pharmaceuticals Inc, the total compensation of Alan Nies at Lexicon Pharmaceuticals Inc is $84,552. There are 16 executives at Lexicon Pharmaceuticals Inc getting paid more, with Lonnel Coats having the highest compensation of $3,870,290.

How old is Alan Nies?

Alan Nies is 82, he's been the Independent Director of Lexicon Pharmaceuticals Inc since 2003. There are no older and 19 younger executives at Lexicon Pharmaceuticals Inc.

What's Alan Nies's mailing address?

Alan's mailing address filed with the SEC is 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS, TX, 77381.

Insiders trading at Lexicon Pharmaceuticals Inc

Over the last 18 years, insiders at Lexicon Pharmaceuticals Inc have traded over $161,951 worth of Lexicon Pharmaceuticals Inc stock and bought 392,158,422 units worth $731,672,961 . The most active insiders traders include International S.C.A.Minne P..., International S.C.A.Wittouc... et Llc Invus, L.P.Invus Adviso.... On average, Lexicon Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $5,348,701. The most recent stock trade was executed by International S.C.A.Wittouc... on 10 May 2024, trading 57,546,100 units of LXRX stock currently worth $97,252,909.

What does Lexicon Pharmaceuticals Inc do?

corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio

Complete history of Alan Nies stock trades at Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc executives and stock owners

Lexicon Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Lonnel Coats,
  President, Chief Executive Officer, Director
• Praveen Tyle,
  Executive Vice President - Research and Development
• Jeffrey Wade,
  Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
• Lonnel Coats,
  CEO & Director
• Alan Main,
  Executive Vice President, Commercial Supply Operations
• Jeffrey L. Wade J.D.,
  Pres & CFO
• Dr. Alan J. Main Ph.D.,
  Exec. VP of Innovation & Chemical Sciences
• Dr. Alan J. Main,
  Exec. VP of Innovation & Chemical Sciences
• Brian T. Crum,
  VP, Gen. Counsel & Sec.
• James Tessmer,
  Vice President - Finance and Accounting
• Raymond Debbane,
  Independent Chairman of the Board
• Samuel Barker,
  Independent Director
• Frank Palantoni,
  Independent Director
• Judith Swain,
  Independent Director
• Philippe Amouyal,
  Independent Director
• Robert Lefkowitz,
  Independent Director
• Christopher Sobecki,
  Independent Director
• Alan Nies,
  Independent Director
• Dr. Robert J. Lefkowitz,
  Consultant & Independent Director
• Brian Crum,
  Vice President, General Counsel
• Dr. Craig B. Granowitz M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Kristen L. Alexander,
  VP of Fin. & Accounting
• Chas Schultz,
  Exec. Director of Corp. Communications & Patient Advocacy
• Sam L Barker,
  Director
• Alexander A Santini,
  EVP and CCO
• Pablo Lapuerta,
  EVP and CMO
• International S.C.A.Wittouc...,
  
• Us Partners Llc Ulys, L.L.C...,
  
• Tamar D Howson,
  EVP of Bus Dev
• Barry Mills,
  Director
• Julia P Gregory,
  EVP and CFO
• James R Phd Piggott,
  SVP of Pharm Bio
• Lance K Ishimoto,
  SVP, Intellectual Property
• Clayton Stuart Rose,
  Director
• Public Equities, L.P.Artal ...,
  
• Public Equities, L.P.Artal ...,
  
• International S.C.A.Minne P...,
  
• Diane E. Sullivan,
  Director
• Thomas Garner,
  SVP, Chief Commercial Officer
• Arthur T Sands,
  Pres & CEO
• John Northcott,
  VP, Marketing, Comm Strategy
• Cv Ulys, L.L.C.Debbane Raym...,
  
• International S.C.A.Minne P...,
  
• Brian P Zambrowicz,
  EVP, Chief Scientific Officer
• Llc Invus, L.P.Invus Public...,
  
• International S.C.A.Invus, ...,
  
• Kathleen M Wiltsey,
  Director
• Llc Invus, L.P.Invus Adviso...,
  
• Philip M Brown,
  SVP Clinical Development
• Steven Alan Tragash,
  VP, Corporate Affairs
• Llc Invus, L.P.Invus Adviso...,
  
• Ajay Bansal,
  EVP Corp Dev and CFO
• Kristen Alexander,
  VP, Finance and Accounting
• C.V. Invus,
  Director
• Craig B Granowitz,
  SVP, Chief Medical Officer
• Kenneth B. Kassler Taub,
  SVP, Regulatory & QA
• Wendy Mc Dermott,
  VP, Human Resources
• Kiernan Seth,
  VP, Chief Commercial Officer
• Michael Exton,
  Chief Executive Officer
• Brian Corrigan,
  SVP, Regulatory & QA